There are 2789 resources available
1433P - Esophageal cancer cell dynamics significantly depended on blood cell circuit, biochemical factors, hemostasis system, cancer characteristics and anthropometric data
Presenter: Oleg Kshivets
Session: ePoster Display
1434TiP - MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Presenter: Daniel Catenacci
Session: ePoster Display
1435TiP - Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
Presenter: Xiaozheng Kang
Session: ePoster Display
1436TiP - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
Presenter: Kohei Shitara
Session: ePoster Display
1438TiP - INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
Presenter: Nick Pavlakis
Session: ePoster Display
1445P - Zoledronic acid quarterly versus monthly conventional schedule in patients with solid tumors with bone metastases
Presenter: Vitor Liutti
Session: ePoster Display